The latest release. There is a lot more info in the whole press release. I have attached a copy of the press release for your review( click the little paper clip next to the smiley face if it doesn't show up)
Dear Dr Byrom
Please find below our current press release. The complete version is attached.
From Oranienburg to the rest of the world: global market launch of Daxas (Roflumilast) kicks off in Germany
- First new substance class in the area of chronic obstructive pulmonary disease (COPD) in more than a decade
- New treatment option for 700,000 patients in Germany with severe COPD and chronic bronchitis
- Improves lung function and reduces exacerbation in combination with bronchodilator treatment
- Daxas - a German success story: research and development in Konstanz; worldwide production in Oranienburg
Stefan Brinkmann, Managing Director of Nycomed GmbH, kicked off the German market launch of Daxas (Roflumilast) in Oranienburg today, making Germany the first country to market the medicine. Daxas is a proprietary selective phosphodiesterase 4 (PDE4) enzyme inhibitor that was developed by Nycomed to treat the progressive, life-threatening lung disease COPD.
Best regards
Corporate Communications
Nycomed International Management GmbH
Thurgauerstrasse 130
CH-8152 Glattpark-Opfikon
Phone +41 44 555 15 10
Fax +41 44 555 15 50
www.nycomed.com
mailto:corporatecommunications@nycomed.com
Dear Dr Byrom
Please find below our current press release. The complete version is attached.
From Oranienburg to the rest of the world: global market launch of Daxas (Roflumilast) kicks off in Germany
- First new substance class in the area of chronic obstructive pulmonary disease (COPD) in more than a decade
- New treatment option for 700,000 patients in Germany with severe COPD and chronic bronchitis
- Improves lung function and reduces exacerbation in combination with bronchodilator treatment
- Daxas - a German success story: research and development in Konstanz; worldwide production in Oranienburg
Stefan Brinkmann, Managing Director of Nycomed GmbH, kicked off the German market launch of Daxas (Roflumilast) in Oranienburg today, making Germany the first country to market the medicine. Daxas is a proprietary selective phosphodiesterase 4 (PDE4) enzyme inhibitor that was developed by Nycomed to treat the progressive, life-threatening lung disease COPD.
Best regards
Corporate Communications
Nycomed International Management GmbH
Thurgauerstrasse 130
CH-8152 Glattpark-Opfikon
Phone +41 44 555 15 10
Fax +41 44 555 15 50
www.nycomed.com
mailto:corporatecommunications@nycomed.com
Attachments
-
32.1 KB Views: 4